GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03364868
Recruitment Status : Recruiting
First Posted : December 7, 2017
Last Update Posted : October 18, 2018
The Leona M. and Harry B. Helmsley Charitable Trust
Helmholtz Zentrum München
University Hospital Carl Gustav Carus
Kinderkrankenhaus auf der Bult
Skane University Hospital
Universitaire Ziekenhuizen Leuven
Medical University of Warsaw
University of Oxford, Clinical Vaccine Research and Immunisation Education
Information provided by (Responsible Party):
Technische Universität München

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 2025
  Estimated Study Completion Date : January 2025